Takanori Yokota
Overview
Explore the profile of Takanori Yokota including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
261
Citations
3012
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimo T, Hasegawa J, Yoshioka K, Nakatsuji Y, Aso K, Tachibana K, et al.
Mol Ther Nucleic Acids
. 2025 Mar;
36(1):102468.
PMID: 40034207
We applied heteroduplex oligonucleotide (HDO) technology, which uses an oligonucleotide hybridized with a complementary strand, to efficiently deliver locked nucleic acid (LNA)-based splice-switching oligonucleotides (SSOs) to the nucleus. Using an...
2.
Iwase R, Ishiguro T, Hara R, Nagata T, Yokota T
ACS Chem Biol
. 2025 Mar;
PMID: 40029284
RNA guanine (G)-quadruplexes (rG4) are unique noncanonical structures composed of stacked guanine quadruplexes that play diverse roles in regulating gene expression, from transcription to protein synthesis. This study proposes a...
3.
Yoshioka Y, Yamamoto S, Kusamori K, Nakayama M, Fujita H, Goto A, et al.
J Control Release
. 2025 Feb;
380:787-799.
PMID: 39947404
Heteroduplex oligonucleotide (HDO) is a novel oligonucleotide therapeutic consisting of an antisense oligonucleotide (ASO) and its complementary RNA. A recent report showed that cholesterol-conjugated HDO (Chol-HDO) exhibited antisense activity in...
4.
Miura M, Shintaku H, Numasawa Y, Ozaki K, Kanouchi T, Ishikawa K, et al.
Neuropathology
. 2025 Feb;
PMID: 39916440
Here, we report an autopsy case of concurrent spinal and bulbar muscular atrophy (SBMA) and multiple system atrophy (MSA). A 55-year-old man presented with weakness, atrophy, and fasciculation of the...
5.
Ishihara T, Tada M, Kanemitsu Y, Takahashi Y, Ishikawa K, Ikenaka K, et al.
EClinicalMedicine
. 2025 Jan;
78():102952.
PMID: 39764542
Background: Therapeutic advancements for the polyglutamine diseases, particularly spinocerebellar degeneration, are eagerly awaited. We evaluated the safety, tolerability, and therapeutic effects of L-arginine, which inhibits the conformational change and aggregation...
6.
Kawai H, Hattori T, Nakajima Y, Yokota T, Onishi I
Neurol Sci
. 2024 Nov;
46(3):1459.
PMID: 39586973
No abstract available.
7.
Kawai H, Hattori T, Nakajima Y, Yokota T, Onishi I
Neurol Sci
. 2024 Nov;
46(3):1451-1453.
PMID: 39546085
No abstract available.
8.
Ishiguro T, Nagata T, Yokota T
Brain Nerve
. 2024 Nov;
76(11):1233-1239.
PMID: 39523616
Since the identification, in 1993, of the causative gene for familial amyotrophic lateral sclerosis (ALS), which is associated with SOD1 mutations, research has focused on the pathogenesis and therapeutics of...
9.
Yokote H, Miyazaki Y, Fujimori J, Nishida Y, Toru S, Niino M, et al.
J Neuroimaging
. 2024 Oct;
34(6):758-765.
PMID: 39390692
Background And Purpose: Slowly expanding lesions (SELs) have been proposed as novel MRI markers of chronic active lesions in multiple sclerosis (MS). However, the mechanism through which SELs affect brain...
10.
Matsubayashi T, Yokoyama K, Tateishi U, Yokota T, Sanjo N
Clin Nucl Med
. 2024 Oct;
49(11):1041-1043.
PMID: 39354691
Although long COVID refers to numerous COVID-19-related symptoms after infection, including depression, fatigue, anosmia, sleep disturbances, and brain fog, the etiology of long COVID remains largely unknown. A 41-year-old woman...